Patents by Inventor Indresh K. Srivastava

Indresh K. Srivastava has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VACCINES AGAINST SARS-COV-2 INFECTIONS
    Publication number: 20240016918
    Abstract: Provided are novel vaccines for prophylactic treatment of SARS-CoV-2 infections and COVID-19 and methods of making the vaccines.
    Type: Application
    Filed: August 23, 2021
    Publication date: January 18, 2024
    Applicant: SANOFI PASTEUR INC.
    Inventors: Natalie ANOSOVA, Salvador Fernando AUSAR, Catherine BERRY, Florence BOUDET, Danilo CASIMIRO, Roman M. CHICZ, Gustavo DAYAN, Guy DE BRUYN, Carlos DIAZGRANADOS, Tong-Ming FU, Marie GARINOT, Lorry GRADY, Sanjay GURUNATHAN, Kirill KALNIN, Nikolai KHRAMTSOV, Valérie LECOUTURIER, Nausheen RAHMAN, Sophie RUIZ, Stephen SAVARINO, Saranya SRIDHAR, Indresh K. SRIVASTAVA, James TARTAGLIA, Timothy TIBBITTS
  • STABILIZED GP120
    Publication number: 20150183835
    Abstract: The present invention provides an isolated polypeptide comprising an HIV gp120 polypeptide or soluble gp140 polypeptide stabilized in a conformation which exposes both CD4-bound and CD4-binding site epitopes. The invention also provides immunogenic compositions and methods of treating and preventing infection with HIV.
    Type: Application
    Filed: June 17, 2013
    Publication date: July 2, 2015
    Inventors: Andrea Carfi, Antu Dey, Aemro Kassa, Indresh K. Srivastava
  • Method of generating an immune response in a subject using fusion proteins comprising CD4 minimal modules and HIV Tat scaffold polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes
    Patent number: 8637044
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: January 28, 2014
    Assignee: Novartis AG
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A Sharma, Indresh K Srivastava, Jan Zur Megede
  • Method for generating immune responses utilizing nucleic acids encoding fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes
    Patent number: 8568734
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: October 29, 2013
    Assignee: Novartis Vaccines and Diagnostics Inc.
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics
    Patent number: 8470334
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: June 25, 2013
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W. Barnett, Indresh K. Srivastava
  • ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE
    Publication number: 20120276141
    Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 1, 2012
    Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
  • Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes
    Patent number: 8226955
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: July 24, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W Barnett, Indresh K Srivastava
  • HIV TAT-CD4 HYBRID MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20120183557
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan BARNETT, Rino RAPPUOLI, Victoria A. SHARMA, Indresh K. SRIVASTAVA, Jan ZUR MEGEDE
  • FUSION PROTEINS COMPRISING CD4 MINIMAL MODULES AND METHODS OF USE THEREOF
    Publication number: 20120177657
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 12, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Vega MASIGNANI, Maria SCARSELLI, Barbara CAPECCHI, Victoria SHARMA, Susan W. BARNETT, Indresh K. SRIVASTAVA, Rino RAPPUOLI
  • Fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutraliziation epitopes
    Patent number: 8206720
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 26, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W. Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Env polypeptide complexes and methods of use
    Patent number: 8197819
    Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 12, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
  • Fusion proteins comprising CD4 minimal modules and human immunodeficiency virus (HIV) Tat scaffold polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes
    Patent number: 8168194
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: May 1, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A. Sharma, Indresh K. Srivastava, Jan Zur Megede
  • Covalently linked complexes of HIV TAT and ENV PROTEINS
    Publication number: 20110257377
    Abstract: Complexes of HIV Env and Tat proteins are advantageous as immunogens compared to Tat or Env alone, but they may dissociate when combined with a vaccine adjuvant. To avoid dissociation, complexes of Env and Tat are stabilized by the use of covalent cross linking. The extent of cross linking is important to the binding properties of the complexes, and so is controlled to avoid the loss of Env's ability to bind specifically to CD4 and Tat's ability to bind specifically to anti-Tat monoclonal antibodies.
    Type: Application
    Filed: March 27, 2007
    Publication date: October 20, 2011
    Inventors: Susan W. Barnett, Indresh K. Srivastava, Elaine C. Kan, Victoria Allen Sharma
  • Multiclade HIV Vaccines
    Publication number: 20110110977
    Abstract: Compositions comprising multivalent and adjuvanted HIV Env glycoproteins are described. Methods of using these compositions for treatment and prevention of HIV are also provided.
    Type: Application
    Filed: October 17, 2006
    Publication date: May 12, 2011
    Inventors: Susan W. Barnett, Raul Victor Gomez-Roman, Brian Burke, Ying Lian, Indresh K. Srivastava
  • Fusion Proteins Comprising CD4 Minimal Modules and Methods of Use Thereof
    Publication number: 20100183653
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Application
    Filed: June 8, 2005
    Publication date: July 22, 2010
    Applicant: CHIRON CORPORATION
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W. Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Hiv Tat-Cd4 Hybrid Molecules and Methods of Use Thereof
    Publication number: 20080317779
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Application
    Filed: February 3, 2006
    Publication date: December 25, 2008
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A. Sharma, Indresh K. Srivastava, Jan Zur Megede
  • Covalently-linked complexes of HIV Tat and Env proteins
    Publication number: 20080300385
    Abstract: Complexes of HIV Env and Tat proteins are advantageous as immunogens compared to Tat or Env alone, but they may dissociate when combined with a vaccine adjuvant. To avoid dissociation, complexes of Env and Tat are stabilized by the use of covalent cross linking. The extent of cross linking is important to the binding properties of the complexes, and so is controlled to avoid the loss of Env's ability to bind specifically to CD4 and Tat's ability to bind specifically to anti-Tat monoclonal antibodies.
    Type: Application
    Filed: March 27, 2007
    Publication date: December 4, 2008
    Inventors: Victoria Sharma, Elaine Kam, Susan W. Barnett, Indresh K. Srivastava
  • Env Polypeptide Complexes and Methods Of Use
    Publication number: 20080199492
    Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.
    Type: Application
    Filed: June 8, 2005
    Publication date: August 21, 2008
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.
    Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
  • HIV-1 vaccines and screening methods therefor
    Publication number: 20020127238
    Abstract: Methods for immunizing, and immunogen pharmaceutical compositions for eliciting a heterologous immune response to HIV-1 in an animal, preferably a human, are provided, utilizing a modified HIV-1 envelope protein or fragment or DNA encoding a modified HIV-1 envelope protein or fragment, the modified protein having a HIV-1 envelope protein V2 region deletion. A humoral response against heterologous HIV-1 strains is achieved.
    Type: Application
    Filed: June 26, 2001
    Publication date: September 12, 2002
    Inventors: Leonidas Stamatatos, Susan W. Barnett, Indresh K. Srivastava